钙调磷酸酶抑制剂在狼疮性肾炎治疗中不断演变的作用
本综述讨论钙调磷酸酶抑制剂(CNI)治疗狼疮性肾炎的选定试验发现与局限,包括单用激素或与霉酚酸酯联合的多靶点治疗。CNI可能对大量蛋白尿及难治性年轻患者有作用,多靶点治疗缓解率高于单用霉酚酸酯或环磷酰胺,但部分试验提示感染不良事件可能更多,需更长期硬终点研究。
要点
- CNI可抑制T细胞功能并经非免疫途径减少蛋白尿,妊娠哺乳期安全。
- 多靶点治疗缓解率高于单用霉酚酸酯或环磷酰胺,但感染不良事件可能更多。
- CNI可能适用于大量蛋白尿及年轻难治性狼疮性肾炎患者。
核心结论
- CNI可能有助于提高狼疮性肾炎缓解率,但现有研究尚未回答的问题仍需更多工作。
研究设计与样本
- 本综述讨论评估CNI治疗狼疮性肾炎的选定试验的发现与局限性。
主要发现
- 多靶点治疗试验显示缓解率高于单用霉酚酸酯或环磷酰胺。
- 部分试验提示多靶点治疗可能感染不良事件更多。
- CNI因非免疫性减少蛋白尿,减量时复发率增加。
临床怎么用
- CNI可能用于大量蛋白尿的狼疮性肾炎患者。
- CNI可能用于年轻难治性狼疮性肾炎患者。
局限性
- 需在更多样化人群中进一步研究CNI。
- 需更长随访及蛋白尿减少之外的硬终点试验,如CKD恶化或重复方案活检。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The overall kidney survival among lupus nephritis patients has improved with currently used induction immunosuppression regimens of corticosteroids and either cyclophosphamide or mycophenolate mofetil; however, there still remains a significant number of lupus nephritis patients who do not achieve remission with these regimens. Investigators have looked at other immunosuppressive regimens for lupus nephritis, and there has been interest in the use of calcineurin inhibitors in this regard. Calcineurin inhibitors are potentially an attractive option because of their established ability to inhibit T cell function, attenuate proteinuria through non-immunologic means, and their safety in pregnancy and lactation. In this review, we discuss the findings and limitations of selected trials that evaluated the use of calcineurin inhibitors in the treatment of lupus nephritis, either with corticosteroids alone or as a component of multitarget therapy when combined with mycophenolate mofetil. There may be a role for calcineurin inhibitors among patients with heavy proteinuria, as well as younger patients with refractory lupus nephritis. The multitarget therapy trials reveal higher rates of remission compared with mycophenolate mofetil alone and cyclophosphamide; however, some trials highlight the possibility of more infectious adverse events. We discuss the need for further study of calcineurin inhibitors in more diverse patient populations and the need for trials with longer follow-up with "hard" endpoints beyond proteinuria reduction, such as worsening CKD or repeat protocol biopsies, given the calcineurin inhibitors ability to reduce proteinuria non-immunologically and thus increased rate of relapse when the drug is tapered. While there may indeed be a space for calcineurin inhibitors to help increase remission rates in lupus nephritis patients, more work is needed to help address the questions the studies available to date have yet to answer.
引用
- Peleg Y, Bomback AS, Radhakrishnan J, et al. The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis. Clin J Am Soc Nephrol. 2020. PMID: 32152065. doi:10.2215/CJN.13761119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。